Currently Viewing:
Evidence-Based Oncology May 2014
Everolimus in Elderly Hormone-Receptor-Positive Advanced Breast Cancer Patients
Jaqueline Rogerio, MD
Stem Cells Create a Therapeutic Niche
Surabhi Dangi-Garimella, PhD
CVS Caremark Quits for Good: Our Decision to Stop Selling Tobacco Products
Troyen A. Brennan, MD, MPH, Chief Medical Officer, CVS Caremark
The Double Whammy of the Obesity Epidemic: Increased Susceptibility to Cancer
Surabhi Dangi-Garimella, PhD
Cheap and Easy-To-Use Diagnostic Tests to Detect Disease Biomarkers, Including Cancer
Surabhi Dangi-Garimella, PhD
The Big Data Revolution: From Drug Development to Better Health Outcomes?
Andrew Smith
Roche Molecular Diagnostic's cobas HPV Test Approved by the FDA
Surabhi Dangi-Garimella, PhD
NCCN Panel Asks What ACA Means to Cancer Care Delivery
Mary K. Caffrey
Fast Track for Prima Biomed's CVac Clinical Trial Development Program
Surabhi Dangi-Garimella, PhD
Understanding Which Therapy Comes First in Treating Castration-Resistant Prostate Cancer
Mary K. Caffrey
Choosing a BRCA Genetic Testing Laboratory: A Patient-Centric and Ethical Call to Action for Clinicians and Payers
Ellen T. Matloff, MS, Rachel E. Barnett, MS, and Robert Nussbaum, MD
New NCCN Prostate Cancer Screening Guidelines Aim for Middle Ground
Mary K. Caffrey
Denlinger Discusses Posttreatment Surveillance for Cancer Survivors
Mary K. Caffrey
More Enthusiasm for Newer Melanoma Therapies
Mary K. Caffrey
When Science Outpaces Payers: Reimbursement in Molecular Diagnostics
Mary K. Caffrey
Mutations That Drive Lung Cancer Also Driving Frontiers of Treatment
Mary K. Caffrey
Promising News in Treating Multiple Myeloma
Mary K. Caffrey
Sorting Through Screening Protocols for Colorectal Cancer
Mary K. Caffrey
Currently Reading
Protecting Bone Health During Cancer Care
Mary K. Caffrey

Protecting Bone Health During Cancer Care

Mary K. Caffrey
NCCN Guidelines Updates
Life-saving therapies that halt cancer can take a toll on the skeletal system, leaving survivors with bone loss or more serious injuries such as broken wrists, ribs, or hips. Watchful attention, screening, and therapy are needed to prevent these outcomes.

Azeez Farooki, MD, an endocrinologist and specialist in cancer-induced bone loss at Memorial Sloan Kettering Cancer Center, presented the findings of the National Comprehensive Cancer Network’s (NCCN’s) Bone Health Task Force on March 13, 2014, at the group’s 19th annual conference—Advancing the Standard of Cancer Care—held in Hollywood, Florida.

Avoiding fractures starts with screening, and Farooki said bone mineral density (BMD) assessments for osteoporosis are recommended in all postmenopausal women 65 years and older, regardless of risk factors, and in all men starting at age 70 years.

Men and women aged 50 to 70 years should receive BMD tests if they have certain risk factors, such as previous fractures, glucocorticoid therapy, parental history of hip fracture, low body weight, excessive alcohol use, or rheumatoid arthritis, or if they are current smokers or have chronic obstructive pulmonary disease. Other risks are premature menopause, malabsorption, chronic liver disease, hypogonadism, and inflammatory bowel disease.

Bone loss with age is normal, Farooki explained, but certain cancer treatments speed up the process more than others. He shared a slide comparing normal bone loss in men at the low end with that of men following various types of cancer treatments. The greatest loss occurred, though, among women experiencing premature menopause and secondary chemotherapy.

While it is common to associate bone loss with women and menopause, Farooki explained that men are also at risk for bone loss and skeletal injury. He noted that while men experience one-third of hip fractures, they experience higher levels of mortality from hip fractures than women: 37.5%, compared with 28.2% in women.

So what to do? Bone health maintenance involves strategies in scans and treatment, including preventive treatment. Farooki went through a number of recommendations.

In early-stage breast cancer, the use of adjuvant bisphosphonates to reduce recurrence and improve survival is currently considered investigational, though there are some promising
data so far in the “low estrogen” state.

In prostate cancer, no bisphosphonate has shown benefit for bone metastasis prevention. Denosumab has been shown to delay the onset of bone metastases in castration-resistant prostate cancer, although the clinical significance has yet to be determined.

Farooki said the NCCN does not recommend the use of osteoclast-targeted therapy for prevention of bone metastases in prostate cancer. He also reviewed the use of antiresorptives—which can help with both the prevention of bone loss generally, and aid in treatment of bone metastases and myeloma—in the prevention of fractures and in the easing of bone pain.

Calcium intake goal should be 1200 mg per day, but work with a nutritionist may be needed, because if supplements are used in excess, patients can be at risk for developing kidney stones.
There are similar recommendations with vitamin D—it is a dietary necessity, but food is a better source, and there is such a thing as too much vitamin D.

Some caveats: estrogen is preferred for young women with premature menopause and non–estrogen-dependent cancer. Raloxifene use with an aromatase inhibitor is not advisable. And denosumab is the only drug recommended for men on androgen deprivation therapy that has solid fracture prevention data.

In response to questions, Farooki said he does recommend that patients work with physical therapists to improve bone strength to prevent fractures, and balance to prevent falls, which can lead to fractures. EBO


At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), held March 12-15, 2014, experts reviewed research and presented updates to the NCCN Clinical Practice Guidelines in Oncology. The conference also featured a roundtable discussion on how the early months of implementing the Affordable Care Act are affecting the delivery of cancer care. Beyond treatment for cancer, NCCN issued updates to last year’s survivorship guidelines as well as new recommendations in the realm of cancer screening.
For complete NCCN guidelines, create a profile and visit: http://www.nccn.org/professionals/default.aspx.
For the August 2013 NCCN Bone Health Task Force Report, visit: http://www.nccn.org/JNCCN/supplements/PDF/bone_health_cancer_care_tf.pdf.
PDF
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up